Back to Results
First PageMeta Content
Pharmaceutical sciences / Emergency contraception / Contraception / Unintended pregnancy / Birth control / Over-the-counter drug / Cervical cap / Levonorgestrel / Food and Drug Administration / Hormonal contraception / Medicine / Pharmacology


RE: FDA Public Hearing on “Using Innovative Technologies and Other Conditions of Safe Use to Expand which Drug Products can be Considered Nonprescription” [Docket No. FDA-2012-N[removed]Statement by Kirsten Moore, Pres
Add to Reading List

Document Date: 2012-04-05 16:43:06

Open Document

File Size: 160,33 KB

Share Result on Facebook

City

Washington / DC / /

Company

Use / Publicly Funded Family Planning Agencies / Innovative Technologies / Pharmacy Access Partnership / Readiness / Health Information Technology / Challenges / /

Country

United States / /

/

IndustryTerm

information technology programs / acceptable technologies / nonprescription product / contraceptive products / retail clinics / information technology / pharmaceutical / /

MedicalCondition

disease / fibroid tumors / endometriosis / premenstrual dysphoric disorder / ovarian cysts / iron-deficiency anemia / /

MedicalTreatment

birth control / emergency contraception / contraception / counseling / /

Organization

FDA / Reproductive Health Technologies Project / United States Government / /

Person

Craig M. Klugman vi / Elizabeth Dawes / Laura A. Davidson / Clare T. Pettis / Amber J. Joiner / Daniel M. Cook / Kirsten Moore / Margaret Hamburg / /

/

Position

Commissioner / pharmacist / President & CEO / /

Product

levonorgestrel / Should / /

ProgrammingLanguage

DC / /

Technology

Telemedicine / lower health care costs.xi Using technology / information technology / simulation / CEO Reproductive Health Technologies / /

URL

http /

SocialTag